New York State Common Retirement Fund Chemo Centryx, Inc. Transaction History

New York State Common Retirement Fund

$73.9 Billion
Q3 2024

Shares

16 transactions

Quarter	Operation	Price Per share	shares change	shares Held	SEC Form
Q3 2022 Nov 08, 2022	BUY	$22.17 - $51.8 $48,397 - $113,079	2,183 Added 4.95%	46,272 $2.39 Million
Q2 2022 Aug 04, 2022	SELL	$15.36 - $27.51 $1.17 Million - $2.09 Million	-75,856 Reduced 63.24%	44,089 $1.09 Million
Q1 2022 May 05, 2022	BUY	$22.22 - $39.12 $1.25 Million - $2.2 Million	56,227 Added 88.24%	119,945 $3.01 Million
Q4 2021 Feb 02, 2022	BUY	$18.38 - $40.5 $454,941 - $1 Million	24,752 Added 63.52%	63,718 $2.32 Million
Q3 2021 Nov 02, 2021	SELL	$13.18 - $19.83 $81,109 - $122,033	-6,154 Reduced 13.64%	38,966 $666,000
Q2 2021 Aug 02, 2021	BUY	$9.59 - $50.88 $4,027 - $21,369	420 Added 0.94%	45,120 $604,000
Q4 2020 Feb 08, 2021	BUY	$47.25 - $65.16 $99,225 - $136,836	2,100 Added 4.93%	44,700 $2.77 Million
Q3 2020 Nov 05, 2020	BUY	$46.35 - $61.69 $83,430 - $111,042	1,800 Added 4.41%	42,600 $2.33 Million
Q2 2020 Aug 07, 2020	BUY	$38.58 - $65.07 $154,320 - $260,279	4,000 Added 10.87%	40,800 $2.35 Million
Q4 2019 Feb 05, 2020	SELL	$6.81 - $39.55 $32,687 - $189,840	-4,800 Reduced 11.54%	36,800 $1.46 Million
Q2 2019 Aug 09, 2019	BUY	$8.31 - $14.85 $134,622 - $240,570	16,200 Added 63.78%	41,600 $387,000
Q3 2018 Nov 07, 2018	SELL	$10.49 - $13.72 $116,439 - $152,292	-11,100 Reduced 30.41%	25,400 $321,000
Q2 2018 Aug 10, 2018	SELL	$10.62 - $13.98 $6,371 - $8,388	-600 Reduced 1.62%	36,500 $481,000
Q4 2017 Feb 13, 2018	SELL	$5.53 - $8.42 $31,321 - $47,690	-5,664 Reduced 13.24%	37,100 $221,000
Q3 2017 Nov 06, 2017	BUY	$6.5 - $10.69 $36,816 - $60,548	5,664 Added 15.27%	42,764 $317,000
Q2 2017 Aug 11, 2017	BUY	N/A	37,100	37,100 $347,000

Others Institutions Holding CCXI

# of Institutions

6

Shares Held

66.3K

Call Options Held

0

Put Options Held

0

About ChemoCentryx, Inc.

Ticker CCXI
Exchange NASDAQ
Shares Outstandng 71,919,696
Market Cap $3.68M
Description
ChemoCentryx, Inc., a biopharmaceutical company, focuses on the development and commercialization of new medications for inflammatory disorders, autoimmune diseases, and cancer in the United States. It offers TAVNEOS (avacopan), an orally administered selective C5aR inhibitor for the treatment of adult patients with severe active anti-neutrophil...

More about CCXI

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of New York State Common Retirement Fund, based on Form 13F filings with the SEC.

News

Stay updated on New York State Common Retirement Fund with notifications on news.